France· FR:61621192
ACARBOSE ARROW 100 mg, comprimé sécable
A acarbose product, registered in France by ARROW GENERIQUES, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Acarbose is registered in 13 of 19 countries.
Countries holding a registration under ATC A10BF01 (acarbose), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 9 of them publish a price we can compare per daily dose
Acarbose · ATC A10BF01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Finlandprice
- Franceprice
- Germany
- Italyprice
- Japan
- Norwayprice
- Polandprice
- Spainprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of acarbose costs, country by country.
Normalised to the WHO defined daily dose (0.3 g), the median price runs from $0.52 in Spain to $1.01 in United States — a ×1.9 gap.
- France: $0.65 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Acarbose · price per daily dose (0.3 g)
USD · FX 28 Sept 2026
- US United States$1.01 (acquisition cost)
- IT Italy$0.96
- FR France$0.65
- ES Spain$0.52
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Manufacturer
- ARROW GENERIQUES
- Country
- France (FR)
- ATC code
- A10BF01
- ATC class
- Acarbose
- Defined daily dose
- 0.3 g, O
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip133400930211465plaquette(s) PVC polyéthylène PVDC aluminium de 90 comprimé(s)EUR 13.87
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
461 interactions on record for acarbose.
Graded by severity as the source publishes them — 8 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Acarbose · interactions on record
461 records
- 8 severe
- 262 moderate
- 46 minor
- 145 info
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- GatifloxacinJ01MA16severe
- PexidartinibL01EX15severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Acarbose in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaACARBOSE VIATRISMylan Ireland Limited, Dublin
- United KingdomAcarbose 100mg tabletsActavis UK Ltd
- United StatesAcarboseHeritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
- SpainACARBOSA FARMALIDER 100 MG COMPRIMIDOSFarmalider S.A.
- ItalyACARBOSIO DOC GENERICIDOC GENERICI S.R.L.
- PolandAcarbose AurovitasAurovitas Pharma Polska Sp. z o.o.
- NorwayAcarbose alALUID PHARMA
- CanadaMAR-ACARBOSEMARCAN PHARMACEUTICALS INC
Authorised across Europe · EMA
The same active substance is authorised in 8 EEA countries. Names it is sold under:
- Bulgaria · Ароба
- Czechia · Acarbose Viatris
- Germany · Acarbose Al, Acarbose Dura
- Spain · Acarbosa Farmalider, Acarbosa Qualigen
- United Kingdom (Northern Ireland) · Acarbose, Acarbose Generics [uk] Ltd
- Italy · Acarbosio Aurobindo, Acarbosio Doc Generici
- Poland · Acarbose Aurovitas, Adeksa
- Portugal · Acarbose Berar Laboratórios Basi - Indústria Farmacêutica, Acarbose Bluepharma
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/da1f3802-aad9-403e-a2d7-92b531b4b63f GET /v1/drugs/da1f3802-aad9-403e-a2d7-92b531b4b63f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "61621192",
"date_amm": "2020-07-16",
"type_amm": "Procédure décentralisée",
"numero_ue": null,
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé sécable",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about acarbose.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.